Multiple Sclerosis | Unmet Need | Chronic Progressive Multiple Sclerosis | US/EU | 2016
No disease-modifying therapies (DMTs) are approved for nonrelapsing, progressive forms of MS, which comprise the majority of chronic progressive multiple sclerosis (CP-MS) patients. Current treatment relies heavily on off-label use of products approved for the treatment of relapsing forms of MS, or anti-inflammatory agents that are not approved at all for MS. This Unmet Need content provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need in CP-MS. We analyze the commercial opportunities and how emerging therapies may capitalize on these opportunities.
Related Market Assessment Reports
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
Report
Osteoarthritic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Osteoarthritic Pain (US)
Osteoarthritic (OA) pain affects more than 30 million people in the United States, and the aging population and rising obesity rates are expected to drive further increases. Current treatments,…
